Related Experiment Videos

[Percutaneous transluminal angioplasty in aortic coarctation. The short- and median-term results]

M Ledesma Velasco1, J L Acosta Valdes, J Munayer Calderón

  • 1Departamento de Hemodinamia y Fisiología Pulmonar, Hospital General Centro Médico la Raza, México, D.F.

Archivos Del Instituto De Cardiologia De Mexico
|January 1, 1991
PubMed

Insights

Percutaneous transluminal angioplasty (PTA) effectively treats aortic coarctation (Ao Co), reducing pressure gradients and improving anatomy. Outcomes vary based on aortic arch hypoplasia severity.

Area of Science:

  • Cardiovascular Interventions
  • Pediatric Cardiology
  • Interventional Radiology

Background:

  • Aortic coarctation (Ao Co) is a congenital heart defect requiring effective treatment.
  • Percutaneous transluminal angioplasty (PTA) offers a less invasive alternative to surgery for Ao Co.

Purpose of the Study:

  • To evaluate the efficacy and safety of PTA in patients with native and post-surgical Ao Co.
  • To assess the impact of aortic arch hypoplasia on PTA outcomes.

Main Methods:

  • PTA was performed in 34 patients with Ao Co using single or dual balloon techniques.
  • Patients were stratified into three groups based on aortic arch hypoplasia severity.
  • Outcomes were assessed by gradient reduction and angiographic improvement during follow-up.

Main Results:

  • Significant gradient reduction and angiographic improvement were observed across all groups.
  • Group III (no hypoplasia) showed the best results (71% gradient drop, 60% improvement).
  • Complications included cerebral hemorrhage, embolism, thrombosis, and aneurysm, with one death.

Conclusions:

  • PTA is a viable treatment option for Ao Co with lower morbidity and mortality than surgery.
  • Treatment success is significantly influenced by the anatomical type of coarctation and degree of aortic arch hypoplasia.

Related Concept Videos